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Summary
Atherosclerosis is a cardiovascular inflammatory
disease that occurs in major arteries and leads to
heart attacks, stroke, and peripheral artery disease.
This disease has a high mortality rate in Europe,
the United States, and much of Asia. Researchers
have developed a strain of genetically modified
mice deficient in ApoE as a model for
antherosclerosis. In this review, we aim to discuss
the current advances at the molecular level and
therapeutic approaches in the treatment of
atherosclerosis.  Two different secretory
phospholipase A2’s (sPLA2), Groups V and X,
hydrolyze low density lipoproteins(LDL) promoting
spontaneous aggregation and generation of lyso-
PC that evokes proatherogenic cellular events,
respectively. The modified LDLs are internalized by
the monocyte-derived macrophages via two
scavenger receptor family members SR-A and
CD36. Active macrophages induce the uptake of
native LDL resulting in macrophage cholesterol
accumulation, referred to as foam cell formation.
Pathways that promote foam cell formation include
lipoprotein lipase expressed in macrophages,
chemokines such as MCP-1 expressed in
monocytes, and fractalkine expressed on activated
endothelial cells. Researchers have discovered that
fractalkine, which undergoes ectodomain shedding
by metalloproteinases, engages G-protein coupled
receptors and upregulates integrins. Moreover, a
single amino acid polymorphism of fractalkine
receptors reduces coronary artery disease in vivo.
There is currently no cure for atherosclerosis, but
several studies have shown ways to treat the
disease by reducing foam cell formation. These
methods include immunization of immunoglobulin
and LDL, anti MCP-1 gene therapy, and the use of
the anti-oxidative effects of pomegranate juice.
Introduction
Atherosclerosis is a pathological process that occurs in
major arteries. It is the underlying cause of heart
attacks, stroke, and peripheral artery disease. Despite
advances in prevention and treatment, atherosclerosis
remains the leading cause of mortality in the United
States. Although well-established risk factors such as
elevated serum cholesterol, high blood pressure,
diabetes, smoking, gender, and obesity have been
identified, these factors do not fully account for an
individual’s risk of cardiovascular disease (CVD).
Genetic factors in addition to those linked to the above
risk factors also play an important role. Identifying these
factors is likely to lead to a better understanding of
pathogenesis and to improved treatment and
prevention strategies.
The symptoms of atherosclerosis are highly
*This paper was written in BIO221 Cellular and Molecular Biology, taught
by Dr. Shubhik DebBurman.
variable. Patients with mild atherosclerosis may have a
myocardial infraction, or sudden cardiac death, which
may be the first sign of coronary heart disease.
However, many patients with an anatomically advanced
disease stage may have no symptoms and experience
no functional impairment.
Atherosclerosis is inflammation of vessel
walls arising from interaction of monocytes with
vascular, endothelial, and smooth muscle
cells (SMC’s) (Combadiere et al., 2003). At the
molecular level, interactions among these cell types
involve low-density lipoproteins (LDL’s), adhesion
molecules, and chemoattractants (Lucas et al., 2003).
One of the first events in atherogenesis is endothelial
activation in an inflammation site leading to close
interactions with the circulating monocytes. Monocytes
adhere to the inflamed endothelium which then migrate
and accumulate in the intima (Lesnik et al., 2003). The
monocyte trafficking is directed by chemokines (Fig. 1)
(Lesnik et al., 2003). Further interactions between
recruited inflammatory cells, the extracellular matrix
(ECM), the resident vascular cells ultimately lead to the
formation of atherosclerotic lesions—accumulation of
plaque, (Lucas et al., 2003).
Many years of study have been conducted to
reveal the biological basis of atherosclerosis at the
celluar and molecular level. The mechanism or pathway
behind the uptake of LDL by monocytes is unknown.
Some of the most common studies for atherosclerosis
are the interaction of monocytes with endothelial cells
and SMC’s along with molecules like LDL, adhesion
molecules, and chemoattractants.
Some of the recent f indings of
atherosclerosis at the molecular level include the role of
macrophages and chemokines.  The purpose of this
article is to review the studies that uncovered the key
pathways of atherosclerosis that make connections
between atherosclerosis and the molecular interactions
at the cellular level. The main topics that will be covered
in this article include the differentiation of monocytes
into macrophages, the modification and uptake of LDL
by monocytes, the role of chemokines in recruitment of
monocytes and vascular SMC’s, and the possible
disease therapies (Fig. 1).
Modification of LDL
Modified LDL’s are recognized by receptors on
macrophages (Fig. 2). Formerly, modified LDL was
thought to be only oxidized or acetylated LDL. Although
this hypothesis is still widely accepted, recent studies
show evidence for the uptake of LDL modified through
different pathways. One such pathway includes the
enzyme Phospohlipase A2 (PLA2). PLA2 is a family of
enzymes that hydrolyzes a fatty acid ester bond of
glycerophopholipids, producing fatty acids and
lysophospholipds. Secretory PLA2 (sPLA2) are low in
molecular weight and require a catalytic amount of Ca2+
for activity. Currently, nine sPLA2’s have been identified
in humans (IB, IIA, IID, IIE, IIF, III, V, X, and XII)
(Hanasaki et al., 2002).
Hydrolysis of LDL by sPLA2-V
Group V sPLA2 hydrolyzes phosphatidylcholine (PC),
which makes up most of the LDL (Wooten-Kee et al.,
2004). Hydrolysis of LDL by sPLA2-V was shown to
promote spontaneous particle aggregation (Wooten-
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Kee et al., 2004). LDL treated with secretory
sphingomylinase (s-SMase) also induces aggregation.
This aggregation is associated with atherogenic lipid
accumulation in the arterial wall.
Both sPLA2-V and s-SMase have been found
in atherosclerotic lesions (Wooten-Kee, 2004). The
ECM also plays an important role in aiding in the
retention of hydrolyzed LDL through co-localization with
sPLA2-V (Wooten-Kee et al., 2004).   These results lead
to the conclusion that sPLA2-V and s-SMase work
together with the ECM to enhance LDL retention as well
as aggregation (Wooten-Kee et al., 2004).
Hydrolysis of LDL by sPLA2-X
LDL treated with sPLA2-X was found to degrade PC at
about the same rate as oxidized LDL. However, the
amount of lyso-PC was increased by about 70%
compared to ox-LDL (Hanasaki et al., 2002). Lyso-PC
is believed to aid in the induction of various chemokines
and cell adhesion molecules (Hanasaki et al., 2002).
Also, the sPLA2-X-treated LDL released more
unsaturated fatty acids, while ox-LDL released more
conjugated dienes due to oxidative stress (Hanasaki et
al., 2002). Uptake of sPLA2-X-treated LDL into
macrophages was also increased, as well as a visible
increase in the size of lipid droplets compared to
macrophages incubated with ox-LDL (Hanasaki et al.,
2002). These results suggest that a sPLA2 inhibitor
could be used to decrease atherogenesis.
Uptake of Modified LDL
Uncontrolled cholesterol accumulation in macrophages
occurs through the internalization of modified LDL (Fig.
1). The modified LDL must first be recognized by a
receptor. This section is dedicated to two prominent
receptors, CD36 and SR-A.
CD36 and  SR-A
CD36 is known to be a receptor for modified
LDL. In the absence of CD36, the uptake of ox-LDL
decreased by about 88% (Febbraio et al., 2004).
Similarly, when bone marrow containing CD36 was
transplanted into CD36
This study was able to differentiate between
knockout mice (CD36-/- mice), there was a 2-fold
increase in plaque development (Febbraio et al., 2004).
macrophage CD36 and CD36 expressed elsewhere
(such as endothelium and muscle cells), indicating that
specifically targeting macrophage CD36 would lead to a
decrease in atherogenesis (Febbraio et al., 2004).
Although CD36 was found to bind and uptake ox-LDL,
extensively modified ox-LDL degrades preferentially
through SR-A indicating that CD36 is preferred only for
mildly oxidized LDL (Kunjathoor et al., 2002). CD36
was found to have a very small affect on ac-LDL. In
contrast, SR-A was found to bind and uptake both ox-
LDL and ac-LDL. Furthermore, in the absence of CD36
and SR-A, degradation of ac-LDL was only decreased
by about 50%, indicating that a different pathway is
used (Kunjathoor et al., 2002).
Foam cell formation
The migration of monocytes to the arterial wall and its
differentiation into macrophages is intended to remove
lipoprotein particles.  The continuous migration of
monocytes and the uptake of modified LDLs by
monocytes and macrophages leads to the development
of atherosclerotic lesions.  The earliest stages of these
lesions are referred to as fatty streaks (Glass et al.,
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Figure 1. Pathology of Atherosclerosis.
A tear in the endothelium attracts the monocytes, which enter the arterial wall. Monocytes uptake low density lipoproteins (LDL), and
differentiate into macrophages.  Macrophages release cytokines that direct migration of monocytes from the blood to the sites of
inflammation. Macrophages uptake more LDL and become foam cells.
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2001).   Recent evidence suggests locomotor forces
are affected by the cholesterol accumulation in
macrophages (Zerbinatti et al., 2003). The presence of
lipoprotein lipase (LPL) promotes foam cell formation
(Fig. 2) (Babaev et al., 2003). Research is continuously
being done to gain an understanding of the
mechanisms underlying foam cell formation.
Macrophage and Locomotion
Monocytes enter the intima and begin to uptake LDL.
Once loaded with cholesterol, the monocyte-derived
macrophages are enlarged (Fig. 1). This excess
cholesterol is delivered to the liver for excretion in bile
acids by macrophages.  The macrophages that turn into
foam cells lose the ability to migrate after excessive
ingestion of modified forms of lipoproteins.  These foam
cells accumulate in the arterial wall because their
mobility is reduced. (Fig. 1) The average and peak
forces generated by the cells and distribution of actin
are all associated with the locomotor force generation
of macrophages. The peak force is used as a
measurement of the locomotor abilities of the cells
(Zerbinatti and Gore, 2003).   When cells were
incubated with oxidized low density lipoprotein (Ox-
LDL), the ability of macrophages to generate average
and peak forces was reduced by 50%.  Cells loaded
with aggregated LDL (Agg-LDL) at the same medium
concentration as Ox-LDL (100 µg protein/ml) had no
significant effect on the forces generated by
macrophages.  Cells loaded with Agg-LDL at
concentrations of 300 µg protein/ml reduced the
magnitude peak force of the macrophages by slightly
less than 50% but had no significant effect on the
average force.  Ox-LDL also reduced the levels of actin
in the cells, whereas Agg-LDL increased the levels of
actin.  The disruption of actin levels affects the cells’
ability to generate normal locomotor forces.  These
results indicate that the cholesterol accumulation is one
of the major factors in the loss of motility in foam cells.
Also, the uptake of Ox-LDL is more effective than Agg-
LDL in disrupting the locomotor forces generated by
macrophages (Zerbinatti and Gore, 2003).
Uptake of LDLs
Studies have shown that modified LDL is a major
source of cholesterol accumulation in monocyte-derived
macrophages.  In previous studies, native LDL was not
shown to cause foam cell formation, because the
cellular receptor that binds native LDL is poorly
expressed on differentiated macrophages.  The
discovery of fluid phase endocytosis— an uptake
pa thway  tha t  can  be  ac t i va ted  i n
macrophages—suggests that LDL uptake and
macrophage cholesterol accumulation do not depend
on LDL binding to receptors (Kruth et al., 2002).  The
activation of monocyte-derived macrophages with a
phorbol ester (PMA) stimulated native LDL uptake,
resulting in massive macrophage cholesterol
accumulation (Fig. 2).  These results show that
modification of LDL is not required for foam cell
formation to take place and that foam cell formation
occurs with native LDL when macrophages are
activated with PMA (Kruth et al., 2002).
Lipoprotein Lipase
LPL is an enzyme that breaks down fat molecules.  This
enzyme is synthesized by the macrophages and by
macrophage-derived foam cells in atherosclerotic
Figure 2. Specific Pathways of Foam Cell Formation.
Chemokines attract more monocytes and VSMCs which bind and uptake modified LDL through SR-A and CD36 receptors. PMA activates
macrophages to take up native LDL. Increased LPL expression increases binding of LDL. Incresed binding and uptake lead to
macrophage formation and furthermore foam cell formation. Foam cell accumulation occurs through decreased locomotor forces.
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lesions. LPL can function as a ligand that promotes
binding of lipoproteins to the LDL receptor (LDLR)-
related protein (Babaev et al., 2000). LDLR-/- mice have
enhanced susceptibility to diet-induced atherosclerosis.
These mice are used as models to study the impact of
macrophage LPL expression at different stages of
atherosclerosis. The mean aortic lesion area was
reduced by 33% in LDLR-/- mice deficient in LPL.  The
extent of atherosclerosis was also significantly reduced
in LDLR-/-LPL-/- and LDLR-/-LPL+/- (heterozygous LPL)
mice.  These results show that the macrophage LPL
expression promotes atherogenesis during the stage of
fatty streak formation (Fig. 2).
Chemokines
Chemokines are a large family of chemoattractants that
direct migration of monocytes from the blood to sites of
inflammation (Fig. 1). Chemokines such as monocyte
chemoattractant protein-1 (MCP-1), interleukin-8 (IL-8),
and fractalkine (FKN) have been identified in human
atherosclerotic lesions.
Ectodomain shedding
Ectodomain shedding, the proteolytic cleavage of cell
surface proteins, is an important mechanism by which
cells regulate the proteins expressed on their surface.
Several types of membrane proteins undergo
ectodomain shedding, including chemokines, tumor
necrosis factor (TNF), growth factors, and adhesion
molecules (Garton et al., 2001). One study (Garton et
al., 2001) showed that TACE (TNF-α-converting
enzyme)—one of the most well characterized
metalloproteinases known to date—cleaved and
shedded FKN, generating soluble FKN. Additionally, the
expression of TACE was upregulated under a variety of
inflammatory conditions in vivo, suggesting that TACE
becomes activated during inflammatory responses
(Satoh et al., 2000). Thus, TACE-mediated cleavage
and ectodomain shedding of FKN is thought to regulate
FKN function in vivo. Previous studies have shown that
FKN can exist either as a membrane-anchored cell
surface protein or as a soluble chemokine. The soluble
form of FKN is known to be a potent chemoattractant
for monocytes and T cells (Bazan et al., 1997).
FKN receptor polymorphism
Later studies by Moatti and colleagues (2001) identified
two common single-nucleotide polymorphisms in the
open reading frame of FKN receptor (CX3CR1),
causing conservative amino acid changes (V249I and
T280M). The study demonstrated that the I249 allele of
the CX3CR1 gene is associated with a reduced risk of
acute coronary events. Decreased expression of
CX3CR1 could have resulted in less efficient interaction
between monocytes and injured endothelium in
subjects exposed to coronary risk factors. Hence, it is
hypothesized that the use of agents blocking the FKN
to CX3CR1 interaction might help prevent the onset
and progression of atherosclerotic lesions.
CX3CR1/FKN pathway
Combadiere and colleagues (2003) identified a direct
and major role for the CX3CR1/FKN pathway in the
development of macrophage-rich atherosclerotic
lesions. Along with the presence of FKN in murine
atherosclerotic plaques, the study showed that FKN-
binding and chemotactic activities were altered in
CX3CR1-/- monocytes compared to controls. Also,
homozygous CX3CR1-/-apoE-/- mice showed a
substantial decrease in macrophage infiltration within
the arterial wall compared to apoE-/- mice alone. The
role of CX3CR1 was further emphasized by a marked
reduction in atherosclerotic lesion size at two different
atherosclerosis-prone sites (aortic sinus and thoracic
aorta) in CX3CR1-/- mice. The aforementioned results
were observed despite similar plasma cholesterol levels
and leukocyte blood counts between the two groups.
Additionally, only one muted CX3CR1 allele was
sufficient to induce the full atherosclerosis phenotype,
thus implying the crucial role for CX3CR1 in
macrophage accumulation in inflammatory sites of
apoE-/- mice. Treatments that interrupt FKN binding to
CX3CR1 are considered a possible treatment of CVD
(Lesnik et al., 2003).
IFN and TNF
In 2003, Lesnik and colleagues demonstrated
prominent FKN expression in macrophage-rich areas of
the lesions, consistent with the analysis of human
atherosclerotic lesions. They suggested that
macrophages are unlikely to be the primary source of
FKN in atherosclerotic sites. Previous in vitro studies
have reported that human SMCs express FKN after
treatment with (IFN-γ) interferon-gamma (Ludwig et al.,
2002). This was confirmed when the combination of
IFN-γ and TNF-α, two cytokines that are known to be
present in atherosclerotic plaques, dramatically
upregulated FKN expression in murine SMCs but not in
macrophages (Lesnik et al., 2003).
Lesnik and colleagues (2003) observed that FKN
staining was not uniform. Moreover, SMCs located
directly beneath lesional macrophages expressed high
levels of FKN. These data suggested that soluble FKN
present on the surface of activated SMCs and/or
endothelial cells plays a direct role in recruiting
monocytes/macrophages into developing inflammation.
This study provided a mechanistic basis for the
observations that patients with FKN receptor
polymorphism have a decreased incidence of coronary
artery disease (Moatti et al., 2001).
Other Chemokines
MCP-1 and IL-8 play important functional roles in
atherogenesis. The individual deletions of MCP-1 (Gu
et al., 1998; Gosling et al., 1999), CCR2 (Boring et al.,
1998), the IL-8 receptor (Boisvert et al., 1998), or
CX3CR1 each resulted in at least a 50% decrease in
atherosclerotic lesion area, suggesting that each of
these chemokines cannot be acting completely
independently. Lesnik and colleagues (2003) proposed
that each cannot be providing completely redundant
functions. They proposed a concerted mechanism of
FKN, MCP-1, and IL-8 to recruit circulating monocytes
into the sub-endothelial space. In this model, FKN and
MCP-1 can be envisioned acting sequentially such that
full-length FKN, along with adhesion molecules, serves
to capture flowing monocytes, which then migrate along
an MCP-1 gradient into the sub-endothelial space.
Evidence for the notion that chemokines can perform
both chemoattractant and adhesive functions in
atherogenesis comes from the work of Huo and
colleagues (2001), which showed that IL-8 captures
flowing monocytes in the mouse carotid artery (Fig. 2).
The relative contributions of full-length and soluble FKN
to atherogenesis can be better explained with the
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creation of mice in which FKN is mutated to a non-
cleavable form.
VSMCs  chemotaxis
Lucas and colleagues (2003) demonstrated that
primary human SMCs express the CX3CR1 receptor
and undergo specific CX3CR1-mediated chemotaxis to
FKN in vitro. They suggested that FKN, rather than
acting as a proinflammatory cytokine in human
atherosclerosis, may play an important role in vascular
remodeling through the recruitment of SMCs into the
atherosclerotic plaque. The ability of FKN to synthesize
substantial amounts of extracellular matrix favors the
development of stable atherosclerotic lesions rather
than macrophage-rich vulnerable plaques (Lucas et al.,
2003). It remains unknown if atherosclerotic plaques
with high levels of FKN progress to stable plaques with
high numbers of SMCs and fibrous caps.
Treatments
Immunoglobulins Treatment
Intravenous immunoglobulins (ivIg) are a solution of
globulins containing antibodies taken from larger pools
of plasma from human blood. In addition to its use as
substitution therapy for primary and secondary antibody
defenses, ivIg is used increasingly in patients with
autoimmune and systemic inflammatory diseases, such
as atherosclerosis (Nicoletti et al., 1998). Although the
mechanism of ivIg is unknown, it may involve the Fc-
and V domains of its structure.   ivIg could regulate the
production of autoantibodies against oxLDL, modulate
T cell functions in plaques, and affect phagocytosis and
cytokine production by macrophages (Nicoletti et al.,
1998). Studies showed that reduction of fatty streaks
was best observed when ivIg was injected into apoE-/-
mice when they were first put on a high-cholesterol diet.
The prevention of atherosclerosis was observed when
ivIg was injected after two months on a high-cholesterol
rather than the beginning of treatment. T cells of ivIg
treated mice exhibited a lower basal proliferation, but
with the addition of a growth factor, T cells could be
induced to proliferate.  This suggests that ivIg inhibits T
cell activation (Nicoletti et al., 1998). The amount of
antibodies to oxLDL was shown to be reduced by ivIg.
LDL immunization
OxLDL in atherosclerotic lesions can stimulate the
recruitment of immune cells (Zhou et al., 2000).  Ten
percent of T cells that are cloned from humans respond
to oxLDL. As a result, humoral and cellular immune
response to oxLDL affects the fate of atherosclerosis.
In previous studies, LDL immunization has been shown
to induce protection against atherosclerosis.  Zhou et
al. (2000) assessed the role of cellular and humoral
immune response involved in this protection. They
showed that immunization with homologous plaque
homogenate as well as homologous malondialdehyde-
LDL inhibits plaque growth. The study also showed that
antibody responses to oxLDL and plaque antigens are
T-cell dependent.
Adenovirus-Mediated Gene Therapy
Macrophage scavenger receptors (MSRs) types AI/II
are membrane glycoproteins that are involved in the
deposition of lipids in the arterial wall during
atherogenesis (Laukkanen et al., 1999).  Modulating the
activity of this receptor could have a major effect on
atherogenesis. To modulate the activity of MSR, an
adenovirus was formed that expressed a secreted
version of human MSR under the control of the
macrophage gene CD68 promoter (Laukkanen et al.,
1999). By using this mechanism, Laukkanen and
colleagues (1999) studied the effects of “decoy”
scavenger receptor on the metabolism of modified LDL
in macrophages. This study showed that the secreted
form of MSR inhibits the accumulation of lipids as well
as foam-cell formation in macrophage tumor cells
(RAW 264). It was confirmed that the binding of
modified LDL to the secreted version of MSR inhibits
the binding of modified-LDL to native MSR.
Anti-MCP-1 Gene Therapy
MCP-1 is a chemokine important for macrophage
recruitment in the arterial wall and its activation. Recent
studies have demonstrated that MCP-1 expression is
increased in atherosclerotic lesions. Blocking the
expression of MCP-1 or its receptor CCR2 decreases
atheroma formation in hypercholesterolemic mice (Ni et
al., 2000). It is still unknown if blockage of the MCP-1
could be a useful site for gene therapy. To assess the
use of gene therapy through the blockage of MCP-1
activity, Ni and colleagues (2000) created a MCP-1
mutant called 7ND in which the N-terminal was deleted.
This mutant has been shown to bind the receptor for
MCP-1 (CCR2) and block MCP-1-mediated monocyte
chemotaxis (Ni et al., 2000). ApoE-/-mice were shown to
have less atherosclerotic lesions when transfected with
the 7ND than with the control. The infiltration of
macrophages into the arterial wall was also reduced in
7ND transfected mice.  For the first time, it was
revealed that blockage of MCP-1 and its receptor CCR2
by transfection of a mutant gene reduces plaque
formation.
Pomegranate Supplementation
The pomegranate tree has been used extensively in
folk medicine of many cultures.  Pomegranate juice (PJ)
contains 85% water, 10% total sugars, and 1.5% pectin,
ascorbic acid and polyphenolic flavonoids.
Pomegranate juice, very rich in flavonoids, was recently
shown to be antiatherogenic, and this effect is probably
related to its potent antioxidative activity. Kaplan and
colleagues (2001), studied the effect of PJ given to
mice with an advanced stage of atherosclerosis. They
showed a significant increase in serum paraoxonase
activity in mice that were given PJ for two month
compared to placebo and control mice.  Serum
paraoxonase is a high density lipoprotein (HDL)-
associated esterase, and it was shown to protect from
oxidation lipids in lipoproteins and in lesions by its
hydrolytic and peroxidative like properties (Kaplan et
al., 2001).  Administration of PJ for two months also
decreased the macrophage lipid peroxidation. The
uptake of oxLDL and atherosclerotic lesion size was
reduced upon treatment with PJ. To date, there have
been no reports indicating whether antioxidant
polyphenols and flavonoids contained in PJ can reverse
oxidation sensitive-genes and increase the expression
of endothelial NO synthase (eNOS).  eNOS synthesizes
nitric oxide (NO), which relaxes the walls of the
coronary arteries and arterioles as well as controls
vascular oxidative stress and the expression of redox-
regulated genes.  Evidence exists that eNOS activity is
reduced at sites of perturbed shear stress (Nigris et al.,
2005).   Nigris and colleagues (2005) showed that
eNOS activity was increased and the expression of
ELK-1 was significantly decreased when examining the
preventive and therapeutic measures of PJ in high and
low atherosclerotic prone areas. However, p-JUN
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expression was only decreased by therapeutic effects
significantly in high-prone areas. Thus, beneficial
effects were elicited by PJ during chronic intervention
(Nigris et al., 2005).
Conclusion
This paper focused on several different cell and
molecular advances in the study of atherosclerosis
within the last five years. LDL can be modified in
various ways, and in all of which they are still able to be
bound and uptaken primarily through CD36 and SR-A
macrophage receptors. Macrophages activated by PMA
can also uptake native LDL. LPL promotes the binding
of LDL to the receptors, thus promoting atherogenesis.
The uptake of modified LDL reduces the mobility of
foam cells, promoting aggregation. Chemokines have
been shown to promote the progression of
atherosclerosis by attracting more monocytes as well
as SMCs to the lesion site. Cleavage of fractalkine and
polymorphism in CX3CR1 play a major role. Although
no cure has been found, creating a non-fucntional
macrophage receptor and blocking the activity of
chemoattractants (such as MCP-1) may have
therapeutic effects. Also, the antioxidant effects of PJ
lead to less oxidation of LDL, therefore reducing foam
cell formation. Although much is known about the
pathways involved in atherosclerosis, there are still
many unanswered questions. In order to better
understand the pathway, it will be necessary to find
other sources of activation of monocytes initiating
uptake of native LDL, the receptor responsible for
degradation of sPLA2-modified LDL, and the pathway of
degradation of ac-LDL. These answers will lead to a
greater understanding of atherogenesis which would
direct relevant research for a cure.
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